China Pharma Holdings, Inc. (CPHI)
NYSEAMERICAN: CPHI · Real-Time Price · USD
0.258
-0.002 (-0.85%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China.

The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions.

Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.

In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets.

Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases.

Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks.

It offers its products through distributors, its network of sales offices, and sales representatives.

The company is based in Haikou, the People’s Republic of China.

China Pharma Holdings, Inc.
China Pharma Holdings logo
Country China
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 231
CEO Zhilin Li

Contact Details

Address:
No. 17, Jinpan Road, Second Floor
Haikou, 570216
China
Phone 86 89 8668 11730
Website chinapharmaholdings.com

Stock Details

Ticker Symbol CPHI
Exchange NYSEAMERICAN
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001106644
CUSIP Number 16941T104
ISIN Number US16941T2033
Employer ID 73-1564807
SIC Code 2834

Key Executives

Name Position
Zhilin Li President, Chief Executive Officer, Chairman and Interim Chief Financial Officer
Huang Na C.F.A. BOD Secretary and IR Manager

Latest SEC Filings

Date Type Title
Nov 1, 2024 PRE 14A Other preliminary proxy statements
Aug 14, 2024 10-Q Quarterly Report
May 30, 2024 8-K Current Report
May 15, 2024 10-Q Quarterly Report
May 8, 2024 8-K Current Report
Apr 1, 2024 10-K Annual Report
Mar 29, 2024 8-K Current Report
Feb 23, 2024 8-K Current Report
Feb 14, 2024 EFFECT Notice of Effectiveness
Feb 8, 2024 8-K Current Report